Applying analgesics to feed is a potentially easy method of providing pain-relief to sheep and lambs that undergo painful husbandry procedures. In order for sheep to consume medicated feed it needs to be know if the medication has an adverse odour or flavour that may affect consumption. It is also important to determine if therapeutic concentrations of a non-steroidal anti-inflammatories (NSAIDs) can be achieved when administered to sheep as a feed supplement. Pelleted feed was supplemented with flunixin (4.0mg/kg liveweight) and administered to eight sheep, which they were able to consume over a 12 h period.
ABSTRACT:
21 Applying analgesics to feed is a potentially easy method of providing pain-relief to sheep and 22 lambs that undergo painful husbandry procedures. In order for sheep to consume medicated feed 23 it needs to be know if the medication has an adverse odour or flavour that may affect 24 consumption. It is also important to determine if therapeutic concentrations of a non-steroidal 25 anti-inflammatories (NSAIDs) can be achieved when administered to sheep as a feed 26 supplement. Pelleted feed was supplemented with flunixin (4.0mg/kg liveweight) and 27 administered to eight sheep, which they were able to consume over a 12 h period. Blood samples 28 were taken over 48 h and plasma drug concentrations were determined using Ultra High Pressure 29 Liquid Chromatography. The mean time required to reach maximum concentration was 6 ± 1.46 30 h and ranged from 1 to 12 h. Average maximum plasma concentration was 1.78 ± 0.17µg/mL 31 and ranged from 1.61 to 2.80 µg/mL. The average half-life of flunixin was 7.95 ± 0.77 h and 32 there was a mean retention time of 13.62 ± 1.17 h. Sheep did not show aversiveness to pellets 33 supplemented with flunixin. When consuming medicated feed ad libitum all sheep were able to 34 obtain inferred therapeutic concentrations of flunixin in plasma within 6 h. Provision of flunixin 35 in the feed may provide a practical way to provide pain relief to sheep and lambs following 36 painful husbandry procedures removing the need for multiple injections, reducing handling stress 37 and minimising labour requirements. 44 Flunixin meglumine is a potent non-steroidal anti-inflammatory (NSAID) that is commonly used 45 in veterinary medicine for its anti-inflammatory, analgesic and antipyretic activity. Like other 46 NSAIDs, flunixin reduces inflammation by inhibiting cyclooxygenase and, in turn, decreasing 47 the production of prostaglandin (Cheng et al. 1998b) , an important inflammatory mediator. 48 Flunixin is known to be effective at relieving pain in various domesticated species such as horses 49 (Keegan et al. 2008; Toutain et al. 1994 ) and cattle (Currah et al. 2009 ) and is currently 50 registered for use for these animals in the US, Europe and Australia (Feely et al. 2002) . Although 78 Palatability test 79 One week prior to the experiment commencing, animals were acclimatised to eating from two 80 troughs and daily food intake was recorded. The palatability test was run for 2 days; in the 81 morning sheep were offered feed in two troughs, one containing 2 kg of the standard animal 90 Pharmacokinetic protocol 91 After the palatability test, the ewes were kept in a paddock for a 2-week flush-out period. They 92 were then returned to the same individual pens that they were in for the palatability test, 1 week 93 prior to the commencement of the pharmacokinetic experiment. The sheep were again fed the 94 complete pelleted ration ad libitum and 100 g of oaten chaff once a day. The day prior to 95 supplementation of feed with flunixin, sheep were weighed and had the wool clipped from their 96 necks. To allow for intensive blood sampling, catheters were inserted aseptically in the jugular 97 vein using a 12 G catheter needle to puncture the vein. A piece of catheter tubing was then 98 threaded through the needle, the line flushed with heparinised saline and then liquid withdrawn 99 till blood was flowing visibly to ensure the catheter was inserted correctly. Catheters were then 100 re-flushed with heparinised saline. The catheter needle was removed and the line was sealed with 101 a three-way tap adaptor containing a leur lock syringe port. The line was secured to the animal at 102 the exit point with Elastoplast tape, the remaining catheter tubing was then encased in 7.5 cm 103 wide Elastoplast bandage which was gently wrapped around the sheep's neck. 104 On the day of the study, sheep were offered 800 g of feed containing a dose of flunixin (at a rate 163 time curve (AUC0-t) was calculated using the linear trapezoidal rule. All parameters were 164 calculated as an overall average as well as for each individual animal. 165 
RESULTS

Palatability
167 Location of the different feeds (left or right trough) had no effect on the amount of each feed 168 (flunixin treated versus untreated) that was consumed. Although overall there was no feed type 169 effect (P=0.10), a trend was observed for the day by feed type interaction (P = 0.08), with 170 animals consuming on average 551 ± 218 g more of the untreated feed than feed containing 171 flunixin (P=0.02) on day 1. On day 2, sheep ate significantly less untreated feed compared to 172 their consumption on day 1 (P=0.03, -490 ± 218g). However, on day 2 there were no differences 241 different between fasted and non-fasted animals with suggesting that the overall concentration of 242 flunixin absorbed is not affected by fasting. In the current study, flunixin was found to be 243 absorbed rapidly when consumed with feed, with detectable levels present within 10 min in 244 sheep that consumed more than 22 g within that period. Flunixin concentrations remained 245 detectable, but were below therapeutic concentrations, 36-40 h after the last medicated food was 246 consumed. Currently there is no toxicity data for flunixin in sheep, however the healthy sheep 247 used in this study did not show any visible side effects as a result of consuming medicated feed. 248 Previous work in cattle by Odensvik (1995; 1998) showed that oral administration of flunixin as 249 a granule inhibited the production of prostaglandin PGF 2 α by up to 60%, which was as effective 250 as the standard therapeutic dose of flunixin (2.2 mg/kg) used parenterally. Although the authors 251 did not directly measure the effectiveness of oral flunixin at reducing inflammation, they 252 concluded that an anti-inflammatory effect was likely due to reduced production of PGF 2 α 253 which acts as a pro-inflammatory following injury (Ricciotti & FitzGerald 2011) . Although 254 further studies are required it is expected that oral administration of flunixin could provide 255 effective pain-relief in sheep. 256 In conclusion, results of this study demonstrates that when flunixin is administered orally 257 through feed to sheep, it is absorbed rapidly into the bloodstream and despite variability in 
